WinstonWınston
Back
Bakhu Holdings logo

Bakhu Holdings

BKUH
Drug Manufacturers - Specialty & Generic · Healthcare
Winston Score
Winston looking sleepy
No score yet — Winston is napping.
We couldn’t gather enough financial data to score this stock reliably.

Winston Score History

The full picture

Bakhu Holdings is a small biotechnology company focused on cannabis-based medicines. It is developing a patented process to extract and formulate compounds from cannabis plants — such as CBD and other cannabinoids — into pharmaceutical-grade products. The company targets the medical cannabis market and aims to supply its formulations to licensed dispensaries, healthcare providers, and pharmaceutical partners.

Bakhu generates little to no revenue today, as it is still in early development and has not yet commercialized its technology at scale. It operates primarily in the United States and holds an exclusive license to its core extraction and delivery technology, which it considers its main competitive advantage. The biggest risk the company faces is the long road from development to commercial sales — it must secure regulatory approvals, find distribution partners, and raise additional capital to survive, all while competing in a crowded and heavily regulated cannabis industry.

Growth Profile

When traditional metrics don't capture the full picture, these are the signals growth stock investors use instead.

Revenue Growth

Revenue data limited

EPS Growth

+70.0% YoY

YoY Growth Rate

EPS growth accelerating

Insider Activity

66.1%ownership

Flat

Insider ownership roughly steady over the past year

Cash Runway

~1 months

$81,519 cash & investments

Short runway — potential dilution ahead through share issuance

Cash watch

Bakhu Holdings has less than a year of cash at its current burn rate. Growth investors should watch for potential share dilution from future fundraising — that directly reduces your ownership.

The Winston Score above measures business quality today. Growth stocks often score lower because they invest in the future rather than maximising current profits. These metrics show what matters most for evaluating that future.

Score breakdown

Every number that matters to educated investors.

Each metric is explained in plain language so you know exactly what you're looking at. Start your free trial now.

Quality

Profit per sale
Gross Margin
N/A
Data not available
Profit after running costs
Operating Margin
N/A
Data not available
Return on the money invested
ROCE
N/A
Data not available

Full breakdown available with your free trial

See every metric, trend, and what it means for this stock.

Try free

Growth

Sales growth
Sales YoY
-200.0%
Shrinking sales (-200.0% YoY)
Profit growth
EPS YoY
N/A
Data not available
How steady the profit is
EPS Consistency
6/8 quarters
Earnings grew in most of the last 8 quarters

Full breakdown available with your free trial

See every metric, trend, and what it means for this stock.

Try free

Cash Flow

Profit that turns into cash
Cash Conversion
-169%
Weak — only -169% of profit becomes cash
Spare cash per sale
FCF Margin
N/A
Data not available

Full breakdown available with your free trial

See every metric, trend, and what it means for this stock.

Try free

Stability

What it owes vs what it owns
Debt / Equity
N/A
Data not available
Covers its interest
Interest Cover
2.26x
Tight — interest eats into profit (2.3x)

Interest coverage between 1 and 3. Profits cover interest, but with little room to spare.

Full breakdown available with your free trial

See every metric, trend, and what it means for this stock.

Try free

Valuation

Price vs profit
P/E Ratio (TTM)
N/M
no trend
Negative earnings — P/E not meaningful
Cheaper or dearer next year
P/E vs Forward
N/A
not available
Data not available

Full breakdown available with your free trial

See every metric, trend, and what it means for this stock.

Try free

Dividends

Not applicable for this business.
🔒 See full fundamentals and if they are improving or declining — click here for your free trial now.
Start free trial